Skip to main content

Advertisement

Table 2 Antibiotic susceptibility of clinical Acinetobacter baumannii isolates

From: Molecular epidemiological study of clinical Acinetobacter baumannii isolates: phenotype switching of antibiotic resistance

Number of isolate 10-10 10-18 29-43 29-4 14-91 14-81
Date of isolation 2-Aug 16-Aug 19-Jul 18-Aug 9-Jun 7-Jul
Time of isolation PM 02:38:55 PM 03:10:10 PM 04:21:03 PM 02:47:06 AM 09:12:47 AM 10:18:53
Diagnosis pneumonia Soft tissue infection pneumonia Catheter-related infection pneumonia pneumonia
Specimens Sputum, tracheal aspirate (suction) abscess Sputum, tracheal aspirate (suction) Tip of central catheter Sputum, tracheal aspirate (suction) Sputum, tracheal aspirate (suction)
Antibiotic Minimum inhibitory concentrations (ug/mL)    
AN 8 128 8 128 8 64
SAM 32 128 32 128 32 128
CTZ 8 64 8 64 8 32
LVF 2 128 2 128 2 64
IMP 2 16 2 16 2 16
PIP-TAZ 8 256 8 256 8 256
CRO 8 128 8 128 8 64
CFP 8 256 8 256 8 128
MEP 4 32 4 32 4 16
  1. Notes: The susceptibility tests were performed using the Vitek-2 GN card (Biomerieux, Marcy l'Etoile, France). The results were interpreted using the CLSI breakpoints (Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility testing; Twenty-First Information Supplement. CLSI document M100-S21, CLSI, Wayne, PA; 2011).
  2. AN: amikacin; SAM: ampicillin-sulbactam; CTZ: ceftazidime; LVF: levofloxacin; IMP: imipenem-cilastatin; PIP-TAZ: piperacillin-tazobactam; CRO: ceftriaxone; CFP:cefepime; MEP: meropenem; colistin and tigecycline and polymyxin B were not provided by Vitek-2 System.